Friday, September 18, 2020

Ampio Pharmaceuticals Inc. [AMPE] moved down -6.84: Why It’s Important

Must read

GAMCO Global Gold Natural Resources & Income Trust [GGN] moved up 2.55: Why It’s Important

GAMCO Global Gold Natural Resources & Income Trust traded at a high on Monday, posting a 2.55 gain after which it closed the...

HTG Molecular Diagnostics Inc. [HTGM] Is Currently 1.85 above its 200 Period Moving Avg: What Dose This Mean?

HTG Molecular Diagnostics Inc. surged by $0.0 during the normal trading session on Thursday and reaching a high of $0.35 during the day...

The Benchmark Company slashes price target on Chembio Diagnostics Inc. [CEMI] – find out why.

Chembio Diagnostics Inc. price surged by 7.91 percent to reach at $0.33. The company report on September 8, 2020 that Chembio Submits EUA...

Gulfport Energy Corporation [GPOR] is -78.10% lower this YTD. Is it still time to buy?

Gulfport Energy Corporation jumped around 0.03 points on Thursday, while shares priced at $0.67 at the close of the session, up 4.16%. The...

Ampio Pharmaceuticals Inc. [AMEX: AMPE] price plunged by -6.84 percent to reach at -$0.08. The company report on July 23, 2020 that Ampio Starts Patient Enrollment in its Ampion COVID-19 Program.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”), is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the Company is actively working on the development of therapies for patients infected with the SARS-CoV-2 virus (“COVID-19”).

Patients are being dosed in a Phase 1 United States based clinical trial evaluating a 5-day intravenous (“IV”) AmpionTM treatment for COVID-19 patients requiring supplemental oxygen. The primary endpoint for this randomized, controlled study will evaluate the safety and tolerability of IV Ampion treatment in adult COVID-19 patients requiring oxygen supplementation. Additional details of the trial can be found on ClinicalTrials.gov (NCT04456452).

A sum of 3657813 shares traded at recent session while its average daily volume was at 3.08M shares. Ampio Pharmaceuticals Inc. shares reached a high of $1.16 and dropped to a low of $1.03 until finishing in the latest session at $1.09.

Guru’s Opinion on Ampio Pharmaceuticals Inc. [AMPE]:

ROTH Capital have made an estimate for Ampio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 19, 2019. While these analysts kept the previous recommendation, Aegis Capital raised their target price from $15 to $16. The new note on the price target was released on March 17, 2014, representing the official price target for Ampio Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $11, while Aegis Capital analysts kept a Buy rating on AMPE stock.

The Average True Range (ATR) for Ampio Pharmaceuticals Inc. is set at 0.11 The Price to Book ratio for the last quarter was 109.00.

AMPE Stock Performance Analysis:

Ampio Pharmaceuticals Inc. [AMPE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 37.80. With this latest performance, AMPE shares gained by 74.40% in over the last four-week period, additionally plugging by 60.27% over the last 6 months – not to mention a rise of 165.85% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMPE stock in for the last two-week period is set at 76.18, with the RSI for the last a single of trading hit 77.90, and the three-weeks RSI is set at 73.66 for Ampio Pharmaceuticals Inc. [AMPE]. The present Moving Average for the last 50 days of trading for this stock 0.6322, while it was recorded at 0.9780 for the last single week of trading, and 0.5532 for the last 200 days.

Insight into Ampio Pharmaceuticals Inc. Fundamentals:

Return on Total Capital for AMPE is now -282.57, given the latest momentum, and Return on Invested Capital for the company is -211.50. Return on Equity for this stock declined to -233.41, with Return on Assets sitting at -97.25. When it comes to the capital structure of this company, Ampio Pharmaceuticals Inc. [AMPE] has a Total Debt to Total Equity ratio set at 22.80. Additionally, AMPE Total Debt to Total Capital is recorded at 18.57, with Total Debt to Total Assets ending up at 10.49. Long-Term Debt to Equity for the company is recorded at 18.78, with the Long-Term Debt to Total Capital now at 15.29.

Reflecting on the efficiency of the workforce at the company, Ampio Pharmaceuticals Inc. [AMPE] managed to generate an average of -$592,609 per employee.Ampio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 0.80.

Ampio Pharmaceuticals Inc. [AMPE] Insider Position Details

There are presently around $18 million, or 13.00% of AMPE stock, in the hands of institutional investors. The top three institutional holders of AMPE stocks are: VANGUARD GROUP INC with ownership of 5,352,988, which is approximately 0% of the company’s market cap and around 8.65% of the total institutional ownership; SRS CAPITAL ADVISORS, INC., holding 1,768,159 shares of the stock with an approximate value of $1.93 million in AMPE stocks shares; and BLACKROCK INC., currently with $1.45 million in AMPE stock with ownership of nearly 1.263% of the company’s market capitalization.

Positions in Ampio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 26 institutional holders increased their position in Ampio Pharmaceuticals Inc. [AMEX:AMPE] by around 3,383,907 shares. Additionally, 23 investors decreased positions by around 2,446,152 shares, while 35 investors held positions by with 10,748,192 shares. The mentioned changes placed institutional holdings at 16,578,251 shares, according to the latest SEC report filing. AMPE stock had 9 new institutional investments in for a total of 1,973,827 shares, while 9 institutional investors sold positions of 1,249,978 shares during the same period.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Market Analysts see L3Harris Technologies Inc. [LHX] gaining to $248. Time to buy?

L3Harris Technologies Inc. stock went on an upward path that rose over 1.79% on Thursday, amounting to a one-week price increase of more...

Option Care Health Inc. [OPCH] Revenue clocked in at $2.78 billion, down -25.07% YTD: What’s Next?

Option Care Health Inc. gained 1.82% on the last trading session, reaching $11.18 price per share at the time. The company report on...

HTG Molecular Diagnostics Inc. [HTGM] Is Currently 1.85 above its 200 Period Moving Avg: What Dose This Mean?

HTG Molecular Diagnostics Inc. surged by $0.0 during the normal trading session on Thursday and reaching a high of $0.35 during the day...

Dynatrace Inc. [DT] moved up 1.89: Why It’s Important

Dynatrace Inc. traded at a high on 09/17/20, posting a 1.89 gain after which it closed the day’ session at $39.85. The results...

why EnLink Midstream LLC [ENLC] is a Good Choice for Investors After New Price Target of $2.97

EnLink Midstream LLC price surged by 1.93 percent to reach at $0.05. The company report on September 11, 2020 that Alerian Index Series...